A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Read more
A Phase 1, First-in-Human, Open- Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms? (the ?Study?). Read more
A Phase 1, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients with Locally Advanced or Metastatic Solid Tumors Read more
A Single Arm Phase II Study to Evaluate Treatment with Gevokizumab in Patients with Stage II/III Colon Cancer who are ctDNA-positive after Curative Surgery and Adjuvant Chemotherapy. Read more
A Phase 1a/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Read more
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitors in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors? under Read more
A Phase 1/2, Open-Label Study Investigating The Safety, Tolerability And Efficacy Of ASP7517 As A Single Agent And In Combination With Pembrolizumab In Patients With Advanced Solid Tumors Known To Express WT1 Antigen Read more
Prospective Collection Of Donor Tissue And Blood Or Leukapheresis Product From Patients With Solid Tumours To Enable Development Of Methods For The Manufacturing Of Clonal Neoantigen T Cell Products (Cnet) Read more
